323 related articles for article (PubMed ID: 24334761)
1. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.
Kachala SS; Bograd AJ; Villena-Vargas J; Suzuki K; Servais EL; Kadota K; Chou J; Sima CS; Vertes E; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
Clin Cancer Res; 2014 Feb; 20(4):1020-8. PubMed ID: 24334761
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.
Servais EL; Colovos C; Rodriguez L; Bograd AJ; Nitadori J; Sima C; Rusch VW; Sadelain M; Adusumilli PS
Clin Cancer Res; 2012 May; 18(9):2478-89. PubMed ID: 22371455
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.
He X; Wang L; Riedel H; Wang K; Yang Y; Dinu CZ; Rojanasakul Y
Mol Cancer; 2017 Mar; 16(1):63. PubMed ID: 28288645
[TBL] [Abstract][Full Text] [Related]
4. Role of mesothelin in carbon nanotube-induced carcinogenic transformation of human bronchial epithelial cells.
He X; Despeaux E; Stueckle TA; Chi A; Castranova V; Dinu CZ; Wang L; Rojanasakul Y
Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L538-49. PubMed ID: 27422997
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.
Suzuki K; Kadota K; Sima CS; Nitadori J; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
J Clin Oncol; 2013 Feb; 31(4):490-8. PubMed ID: 23269987
[TBL] [Abstract][Full Text] [Related]
6. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
Kim YJ; Hong S; Sung M; Park MJ; Jung K; Noh KW; Oh DY; Lee MS; Oh E; Shin YK; Choi YL
Oncotarget; 2016 Dec; 7(50):82876-82888. PubMed ID: 27756880
[TBL] [Abstract][Full Text] [Related]
7. Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: a proposal to reclassify T1 lung adenocarcinoma.
Nitadori JI; Colovos C; Kadota K; Sima CS; Sarkaria IS; Rizk NP; Rusch VW; Travis WD; Adusumilli PS
Chest; 2013 Nov; 144(5):1622-1631. PubMed ID: 23807749
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract][Full Text] [Related]
9. TROP2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells.
Li Z; Jiang X; Zhang W
Biochem Biophys Res Commun; 2016 Jan; 470(1):197-204. PubMed ID: 26773504
[TBL] [Abstract][Full Text] [Related]
10. ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma.
Zheng YZ; Ma R; Zhou JK; Guo CL; Wang YS; Li ZG; Liu LX; Peng Y
Sci Rep; 2016 Nov; 6():36447. PubMed ID: 27830754
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of GATA binding protein-3 expression in primary lung adenocarcinoma.
Hashiguchi T; Miyoshi H; Nakashima K; Yokoyama S; Matsumoto R; Murakami D; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Hum Pathol; 2017 May; 63():157-164. PubMed ID: 28322854
[TBL] [Abstract][Full Text] [Related]
12. Imbalance in redox status is associated with tumor aggressiveness and poor outcome in lung adenocarcinoma patients.
Lisbôa da Motta L; Müller CB; De Bastiani MA; Behr GA; França FS; da Rocha RF; Minotto JB; Meurer RT; Fernandes MC; Roehe A; Markoski MM; Andrade CF; Castro MA; Klamt F
J Cancer Res Clin Oncol; 2014 Mar; 140(3):461-70. PubMed ID: 24449404
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 90-β over-expression is associated with poor survival in stage I lung adenocarcinoma patients.
Wu Y; Huang B; Liu Q; Liu Y
Int J Clin Exp Pathol; 2015; 8(7):8252-9. PubMed ID: 26339394
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of CD133 expression in stage I lung adenocarcinomas.
Woo T; Okudela K; Mitsui H; Yazawa T; Ogawa N; Tajiri M; Yamamoto T; Rino Y; Kitamura H; Masuda M
Int J Clin Exp Pathol; 2010 Dec; 4(1):32-42. PubMed ID: 21228926
[TBL] [Abstract][Full Text] [Related]
15. Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.
Lamberts LE; de Groot DJ; Bense RD; de Vries EG; Fehrmann RS
Oncotarget; 2015 Sep; 6(29):28164-72. PubMed ID: 26172299
[TBL] [Abstract][Full Text] [Related]
16. Tumorigenic role of orphan nuclear receptor NR0B1 in lung adenocarcinoma.
Oda T; Tian T; Inoue M; Ikeda J; Qiu Y; Okumura M; Aozasa K; Morii E
Am J Pathol; 2009 Sep; 175(3):1235-45. PubMed ID: 19644015
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways.
Chang MC; Chen CA; Chen PJ; Chiang YC; Chen YL; Mao TL; Lin HW; Lin Chiang WH; Cheng WF
Biochem J; 2012 Mar; 442(2):293-302. PubMed ID: 21999204
[TBL] [Abstract][Full Text] [Related]
18. Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries.
Hsu HJ; Tung CP; Yu CM; Chen CY; Chen HS; Huang YC; Tsai PH; Lin SI; Peng HP; Chiu YK; Tsou YL; Kuo WY; Jian JW; Hung FH; Hsieh CY; Hsiao M; Chuang SS; Shen CN; Wang YA; Yang AS
Sci Rep; 2021 Jul; 11(1):15430. PubMed ID: 34326410
[TBL] [Abstract][Full Text] [Related]
19. Mesothelin promotes invasion and metastasis in breast cancer cells.
Wang Y; Wang L; Li D; Wang HB; Chen QF
J Int Med Res; 2012; 40(6):2109-16. PubMed ID: 23321167
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of regulator of G protein signaling 11 promotes cell migration and associates with advanced stages and aggressiveness of lung adenocarcinoma.
Yang SH; Li CF; Chu PY; Ko HH; Chen LT; Chen WW; Han CH; Lung JH; Shih NY
Oncotarget; 2016 May; 7(21):31122-36. PubMed ID: 27105500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
